Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.05 USD | +3.68% | 0.00% | +28.42% |
02-28 | Top Midday Decliners | MT |
02-28 | Top Premarket Decliners | MT |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company shows low valuation levels, with an enterprise value at 0.27 times its sales.
- The company appears to be poorly valued given its net asset value.
- Analyst opinion has improved significantly over the past four months.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+28.42% | 166M | B | ||
-3.43% | 184B | C+ | ||
-1.81% | 107B | C | ||
-4.15% | 67.52B | A | ||
+1.43% | 50.06B | B- | ||
+11.60% | 45.67B | B- | ||
+3.21% | 41B | B+ | ||
+3.03% | 26.73B | B | ||
+3.21% | 26.47B | A- | ||
+15.75% | 25.05B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- INGN Stock
- Ratings Inogen, Inc.